Virax Biolabs Group Balance Sheet Health
Financial Health criteria checks 6/6
Virax Biolabs Group has a total shareholder equity of $6.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $7.0M and $919.0K respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$5.21m |
| Equity | US$6.11m |
| Total liabilities | US$919.05k |
| Total assets | US$7.03m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: VRAX's short term assets ($6.0M) exceed its short term liabilities ($787.0K).
Long Term Liabilities: VRAX's short term assets ($6.0M) exceed its long term liabilities ($132.0K).
Debt to Equity History and Analysis
Debt Level: VRAX is debt free.
Reducing Debt: VRAX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VRAX has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: VRAX is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.